Date
- Wednesday, 30 November 2011, All day
Location
- European Medicines Agency, Amsterdam, the Netherlands
Day 2: This meeting includes an introduction from the new Executive Director. Some of the general issues for discsussion at the meeting are the implementation of the anti-falsification legislation; additional monitoring of medicines and direct patient reporting; legislation on information to patients; results of survey project on representativeness in Agency stakeholder groups; outcome of the scientific advisory group pilot phase; and process for re-evaluation of eligibility.Registration by invitation only.